La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Recordati Industria Chimica e Farmaceutica Croissance future
Future contrôle des critères 4/6
Recordati Industria Chimica e Farmaceutica devrait augmenter ses bénéfices et son chiffre d'affaires de 11.2% et de 5% par an respectivement. Le BPA devrait croître de de 11% par an. Le rendement des capitaux propres devrait être 23.9% dans 3 ans.
Informations clés
11.1%
Taux de croissance des bénéfices
10.9%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 15.3% |
| Taux de croissance des recettes | 5.1% |
| Rendement futur des capitaux propres | 23.9% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 20 Aug 2024 |
Mises à jour récentes de la croissance future
Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 31% And Analysts Are Revising Their Forecasts
Aug 02
Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 8.5% And Analysts Are Revising Their Forecasts
May 10Recent updates
We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Aug 20Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 31% And Analysts Are Revising Their Forecasts
Aug 02Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Business Is Yet to Catch Up With Its Share Price
Aug 01Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
May 26Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.63
May 10Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.63
Apr 25Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Share Price Could Signal Some Risk
Apr 23If EPS Growth Is Important To You, Recordati Industria Chimica e Farmaceutica (BIT:REC) Presents An Opportunity
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.63
Mar 23Is Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 27We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Jan 09Risks To Shareholder Returns Are Elevated At These Prices For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.57
Nov 12Is Recordati Industria Chimica e Farmaceutica (BIT:REC) Using Too Much Debt?
Sep 29Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 08Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 23Does This Valuation Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Imply Investors Are Overpaying?
Jun 05Recordati Industria Chimica e Farmaceutica's (BIT:REC) Conservative Accounting Might Explain Soft Earnings
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.60
Apr 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.60
Mar 19Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Mar 06A Look At The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Dec 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.55
Nov 11Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Intrinsic Value Is Potentially 42% Above Its Share Price
Sep 01These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Aug 07An Intrinsic Calculation For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Suggests It's 25% Undervalued
Jun 03Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 16Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 02Recordati Industria Chimica e Farmaceutica's (BIT:REC) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 18Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.57
Apr 04Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.57
Mar 21These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Mar 06Calculating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has A Pretty Healthy Balance Sheet
Dec 05Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Sep 05A Look At The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Jun 25Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 07Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 8.5% And Analysts Are Revising Their Forecasts
May 10Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Shares Could Be 34% Above Their Intrinsic Value Estimate
Mar 11Here's What You Should Know About Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) 2.4% Dividend Yield
Feb 19Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Jan 30Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 2,576 | 566 | 626 | 704 | 7 |
| 12/31/2025 | 2,470 | 520 | 575 | 659 | 8 |
| 12/31/2024 | 2,328 | 448 | 635 | 688 | 7 |
| 6/30/2024 | 2,224 | 387 | 114 | 481 | N/A |
| 3/31/2024 | 2,139 | 389 | 154 | 528 | N/A |
| 12/31/2023 | 2,082 | 389 | 102 | 485 | N/A |
| 9/30/2023 | 2,032 | 375 | 134 | 510 | N/A |
| 6/30/2023 | 2,005 | 389 | 438 | 507 | N/A |
| 3/31/2023 | 1,985 | 340 | 360 | 456 | N/A |
| 12/31/2022 | 1,853 | 312 | 367 | 462 | N/A |
| 9/30/2022 | 1,801 | 331 | 391 | 485 | N/A |
| 6/30/2022 | 1,702 | 330 | 422 | 504 | N/A |
| 3/31/2022 | 1,615 | 393 | 445 | 491 | N/A |
| 12/31/2021 | 1,580 | 386 | 404 | 492 | N/A |
| 9/30/2021 | 1,511 | 377 | 373 | 475 | N/A |
| 6/30/2021 | 1,460 | 365 | 303 | 413 | N/A |
| 3/31/2021 | 1,404 | 334 | 259 | 425 | N/A |
| 12/31/2020 | 1,449 | 355 | 272 | 404 | N/A |
| 9/30/2020 | 1,475 | 389 | -112 | 362 | N/A |
| 6/30/2020 | 1,499 | 391 | -84 | 388 | N/A |
| 3/31/2020 | 1,528 | 388 | -101 | 336 | N/A |
| 12/31/2019 | 1,482 | 369 | -125 | 319 | N/A |
| 9/30/2019 | 1,439 | 328 | 210 | 318 | N/A |
| 6/30/2019 | 1,399 | 322 | 202 | 301 | N/A |
| 3/31/2019 | 1,369 | 318 | 249 | 346 | N/A |
| 12/31/2018 | 1,352 | 312 | 273 | 358 | N/A |
| 9/30/2018 | 1,338 | 307 | 270 | 362 | N/A |
| 6/30/2018 | 1,333 | 306 | 210 | 307 | N/A |
| 3/31/2018 | 1,313 | 297 | N/A | 277 | N/A |
| 12/31/2017 | 1,288 | 289 | N/A | 273 | N/A |
| 9/30/2017 | 1,255 | 275 | N/A | 244 | N/A |
| 6/30/2017 | 1,217 | 262 | N/A | 286 | N/A |
| 3/31/2017 | 1,194 | 250 | N/A | 273 | N/A |
| 12/31/2016 | 1,154 | 237 | N/A | 255 | N/A |
| 9/30/2016 | 1,126 | 229 | N/A | 266 | N/A |
| 6/30/2016 | 1,096 | 218 | N/A | 261 | N/A |
| 3/31/2016 | 1,074 | 212 | N/A | 258 | N/A |
| 12/31/2015 | 1,048 | 199 | N/A | 247 | N/A |
| 9/30/2015 | 1,030 | 190 | N/A | 231 | N/A |
| 6/30/2015 | 1,019 | 181 | N/A | 217 | N/A |
| 3/31/2015 | 1,003 | 170 | N/A | 198 | N/A |
| 12/31/2014 | 987 | 161 | N/A | 179 | N/A |
| 9/30/2014 | 982 | 156 | N/A | 192 | N/A |
| 6/30/2014 | 972 | 146 | N/A | 167 | N/A |
| 3/31/2014 | 957 | 139 | N/A | 167 | N/A |
| 12/31/2013 | 942 | 134 | N/A | 171 | N/A |
| 9/30/2013 | 910 | 127 | N/A | 147 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de REC ( 11.2% par an) est supérieure au taux d'épargne ( 2.4% ).
Bénéfices vs marché: Les bénéfices de REC ( 11.2% par an) devraient croître plus rapidement que le marché Italian ( 6.8% par an).
Croissance élevée des bénéfices: Les bénéfices de REC devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de REC ( 5% par an) devrait croître plus rapidement que le marché Italian ( 3.9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de REC ( 5% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de REC devrait être élevé dans 3 ans ( 23.9 %)